These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1584 related articles for article (PubMed ID: 23771985)

  • 21. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
    Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
    Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
    Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
    Cytotherapy; 2018 May; 20(5):706-714. PubMed ID: 29580864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The efficacy and safety of rituximab in treatment of Epstein-Barr virus disease post allogeneic hematopoietic stem-cell transplantation].
    Xu LP; Liu DH; Liu KY; Zhang CL; Wang FR; Wang JZ; Wang Y; Chen H; Zhang YY; Yan CH; Han W; Chen YH; Zhao T; Zhang XH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):966-70. PubMed ID: 23327959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.
    Kinch A; Hallböök H; Arvidson J; Sällström K; Bondeson K; Pauksens K
    Leuk Lymphoma; 2018 May; 59(5):1172-1179. PubMed ID: 28831836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
    Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
    Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
    Ferguson NN; Thomas CP; Hohl RJ; Syrbu SI; Stone MS; Wanat KA
    Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
    Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
    Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
    Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD;
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Xu LP; Liu DH; Liu KY; Chen H; Han W; Wang Y; Wang J; Shi HX; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):955-8. PubMed ID: 21211211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.
    Xu LP; Zhang CL; Mo XD; Zhang XH; Chen H; Han W; Chen YH; Wang Y; Yan CH; Wang JZ; Wang FR; Zhao T; Liu YR; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2185-2191. PubMed ID: 26253005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
    Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
    Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
    Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
    Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.